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A B S T R A C TNew vaccines have been demonstrated to be effective in reducing
morbidity and mortality, particularly in children, but come at increased
costs to societies, governments, and their national immunization
programs compared with other traditional childhood vaccines. Rational
allocation of available resources requires systematic collection of the
evidence base to decide whether to introduce a new vaccine, an
important component of which is cost-effectiveness analysis. In this
article, we develop in-depth case studies to examine the country
experience of conducting cost-effectiveness analysis with the support
of Pan American Health Organization ProVac Initiative and the implica-
tions of its process for decision making on new vaccine introduction in
Latin America and the Caribbean. Key lessons regarding how cost-
effectiveness analysis may be effectively used to inform evidence-basednt matter Copyright & 2012, International Society
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ondence to: Cara Janusz, C/o PAHO, 525 23rd Streetimmunization policy are highlighted, drawing from the experience of
Nicaragua and Paraguay. Based on the lessons identified, the vision
going forward will focus on promoting the sustainability of multi-
disciplinary country teams while continuing to prioritize capacity
development as an overarching guiding principle for preparing countries
to face future new vaccine policy decisions.
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New vaccines hold the extraordinary potential of saving lives and
preventing disability but come at increased costs to governments
and their national immunization programs. Considering the large
investment new vaccines represent for many programs, the
decision to introduce a new vaccine into a universal immuniza-
tion schedule is a highly complex task [1,2]. Efficient allocation of
available resources requires systematic review of the local evi-
dence base to decide whether to invest public funds in a new
vaccine. One component of the evidence base is economic
analysis, including, among others, cost-effectiveness analysis
[3]. Increasingly, national immunization programs in low- and
middle-income countries are seeking ways to estimate theeconomic and financial burden as well as potential health gains
of new vaccine introduction to ensure financial sustainability and
efficient resource allocation in the long term [4]. As low- and
middle-income countries assume greater financial responsibility
for their national immunization program budgets, questions
around financial sustainability and competition of resources
among different health priorities become more relevant [5].
Ensuring sustainable vaccine introductions as well as efficient
and equitable allocation of resources for health means that
national public health decision makers must invest the time to
collect the evidence base necessary to inform the decision-
making process [1]. The Pan American Health Organization
(PAHO), the regional office of the World Health Organization
(WHO) for the Americas, provides technical assistance tofor Pharmacoeconomics and Outcomes Research (ISPOR).
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Table 1 – ProVac supported country-led economic eva-
luations conducted in LAC.
Country-led economic
evaluations
Countries
Cost-effectiveness analysis of
pneumococcal conjugate
vaccines
Argentina, Bolivia, Costa Rica,
Ecuador, El Salvador,
Guatemala, Nicaragua,
Paraguay, Peru
Cost-effectiveness analysis of
rotavirus vaccines
Argentina, Guatemala
Cost-effectiveness analysis of
HPV vaccines
Argentina, Bolivia, Ecuador,
Jamaica, Paraguay, Uruguay
Costing of HPV delivery
strategies
Barbados
Costing of EPI Bolivia
EPI, Expanded Program for Immunization; HPV, human papillo-
mavirus. LAC, Latin America and the Caribbean.
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and promote this process. Specifically, PAHO’s ProVac Initiative
has extended support to countries to build local evidence bases
to inform decisions regarding the introduction of new vaccines
[6]. The rationale and structure of the ProVac Initiative have been
previously described [1,2,6]. In this article, we develop in-depth
case studies to describe the country experience of conducting
cost-effectiveness analyses (CEA) and developing local evidence
bases to inform decision-making processes in LAC countries. The
case studies reveal several lessons regarding the use of CEA
to inform evidence-based immunization policy.
Supporting Country-Led Economic Analyses: ProVac’s
Approach to Strengthening Evidence-Based Immunization
Policy
With support from the Bill and Melinda Gates Foundation, PAHO’s
ProVac Initiative was established to strengthen national capacity
to perform economic analyses on new vaccines and to use the
evidence to guide the decision-making process. While the ProVac
Initiative promotes the development of a comprehensive evi-
dence base to inform the decision on whether to introduce a new
vaccine or not, drawing from technical, operational, and social
criteria, its primary focus to date has been to respond to country
requests to strengthen their capacity to conduct and to use
economic analyses as one component of the evidence required
for the introduction of new vaccines in the region [1,2,6].
ProVac helps countries to establish multidisciplinary teams and
then supports these multidisciplinary teams to gather evidence for
economic analyses on new vaccines, conduct the analyses, con-
textualize results with other evidence criteria related to the intro-
duction of new vaccines, andmessage results to relevant authorities,
either ministries of health or National Immunization Technical
Advisory Groups (NITAGs). Central to the ProVac approach has been
ensuring that multidisciplinary national teams include collaborators
from several government agencies and disciplines—health econo-
mists, immunization program managers and staff, clinicians from
health care organizations, and experts in related disciplines from
academia. ProVac promotes local stakeholder ownership over the
data collection and analysis process to bolster national capacity to
conduct future studies and to establish a strong, sustainable
foundation for evidence-based immunization policy.
Efforts have resulted in a number of country-led economic
analyses, including 17 CEAs to inform national decision making
around the introduction of new vaccines. Nine studies have been
performed on the pneumococcal conjugate vaccines in Argen-
tina, Bolivia, Guatemala, Costa Rica, Ecuador, El Salvador, Para-
guay, Peru, and Nicaragua, two studies on the rotavirus vaccines
in Argentina and Guatemala, and six studies on human papillo-
mavirus vaccine in Argentina, Bolivia, Ecuador, Jamaica, Paraguay,
and Uruguay (Table 1). Case studies from Nicaragua and Paraguay
illustrate how the locally derived quantitative results are critical for
new vaccine policymaking at the national level, but also how the
process renders many other important inputs for the decision-
making process. Evaluating these case studies reveals key opportu-
nities for the ProVac Initiative to continue bolstering national
capacity around evidence-based immunization policymaking.Case Studies on the Use of Decision Support Models
for New Vaccine Policymaking
In the Americas, nearly 12% of all-cause mortality among
children younger than 5 years is attributed to pneumonia. Of
the estimated 284,248 all-cause deaths among children younger
than 5 years in LAC countries that occurred in 2008, 4366 deaths
were caused by meningitis and 33,798 deaths were caused bypneumonia [7]. Pneumococcal infection is an important patho-
genic cause of these deaths and other serious diseases in
children, including meningitis and sepsis. With the licensure of
two efficacious vaccines to prevent pneumococcal infection in
children, many countries in the Americas have sought to evalu-
ate the cost-effectiveness of introducing either the 10-valent
pneumococcal conjugate vaccine (PCV-10) or the 13-valent pneu-
mococcal conjugate vaccine (PCV-13) as one component of the
necessary evidence base to inform the decision-making process.
In collaboration with the London School of Hygiene and Tropical
Medicine, PAHO’s ProVac Initiative has developed an integrated
childhood vaccination cost-effectiveness model (TRIVAC) for coun-
tries to use and to apply in their local decision-making process. A
user-friendly, Excel-based cohort model, TRIVAC evaluates the
costs, health benefits, and cost-effectiveness of introducing Hib,
rotavirus, or pneumococcal conjugate vaccines. TRIVAC has pre-
loaded data available from international sources for demography,
vaccine coverage, disease burden, health service utilization, and
costs, but national ProVac teams are encouraged to challenge and
improve these estimates with local estimateswhere quality data are
available. The model allows users to evaluate a series of possible
scenarios favorable and unfavorable to the vaccine by varying
parameters such as community herd immunity, vaccine serotype
replacement, and waning protection. Because there may be a great
deal of uncertainty around these parameters in the initial years of
new vaccine introduction, ProVac generally encourages countries to
consider these factors in alternative scenarios to the base-case
scenario. By modeling these alternative scenarios, the TRIVAC
model assesses the effect of such uncertain parameters on primary
model outcomes. In addition, the TRIVAC model features options to
conduct sensitivity analyses. Further description of TRIVAC model’s
methods are presented in the forthcoming article by Clark et al [8].Experience from Nicaragua
In 2009, Nicaragua began weighing the option to introduce one of
the two available WHO prequalified vaccines to prevent pneu-
mococcal pneumonia and other invasive disease. Alongside plans
to implement sentinel surveillance sites for bacterial pneumonia
and meningitis, the Ministry of Health requested support to
undertake special studies to inform the decision-making process.
One such request was for support from PAHO’s ProVac Initiative
to evaluate the cost-effectiveness of introducing a pneumococcal
conjugate vaccine into the routine vaccination schedule.
The Ministry of Health established a national team to perform
the study, including participation from the national Expanded
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ician dedicated full time to coordinate the study, and the PAHO
immunization focal point, a trained infectious disease epidemiol-
ogist. The country team drafted a data collection plan around the
TRIVAC model parameters: demography, disease burden, vaccine
efficacy, serotype coverage, immunization coverage, incremental
program costs, health service utilization, and treatment costs. In
the following months, the country team coordinator organized
meetings for interviews and data extraction with relevant actors
in the Ministry of Health and local hospitals.
The national team agreed on a series of assumptions that would
form the base-case scenario for evaluating the introduction of each
vaccine (Table 2). For both PCV-10 and PCV-13, the base-case
scenario assumed the implementation of a three dose primary
schedule without a booster (3þ0) for children beginning in 2011.
The base-case scenario evaluated 20 successive cohorts of children
younger than 5 years. Because treatment costs saved by familiesTable 2 – Qualitative description of assumptions, processes, an
analyses in Nicaragua and Paraguay.
Assumptions,
processes, and
outcomes
Nicaragua
Vaccines evaluated PCV-10 and PCV-13
Base-case
assumptions
 3þ0 schedule
 Evaluation period 2011–2030
 Societal perspective
 3% discounting for costs and health benefit
Local vs.
international data
sources
Demography  National Census (2005) and national
demographic projections
Disease burden  Regional disease burden studies and
outpatient registries
Vaccine efficacy  Clinical trials and Cochrane review
Immunization
coverage
 Historical DPT3 coverage
Incremental EPI
costs
 Local costing exercise for nonvaccine costs
Health service
utilization
 Ministry of Health study (2004) and Nationa
household surveys (2005)
Treatment costs  Local costing study in three subsectors (201
Duration of study 7 mo
Country team
composition
 EPI manager
 Public health clinician
 PAHO country immunization advisor
Flow of CEA results Final results presented to Ministry of Health
authorities
Process outcomes  Decision to introduce PCV-13 with PPP
support
 Government report exploring financial
sustainability of PCV-13 in the absence of P
support
Uncertainty
analyses?
Scenario analysis
CEA, cost-effectiveness analysis; DPT3, third dose of diphtheria-tetanu
private-public partnership; NITAG, National Immunization Technical Ad
valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococc
* Study coordinator.were considered important to the national government, the study
was conducted from the societal perspective, including costs borne
by the government and by households, such as transportation
costs, fees to access private services, and foregone earnings by
caretakers. The team also received training to perform scenario
analysis to evaluate a series of scenarios favorable and unfavorable
to the vaccines.
For each model parameter, the country team reviewed gov-
ernment databases, hospital registries, and billing reports for
procedure and treatment costs associated with managing inva-
sive pneumococcal disease cases. After an extensive review, the
team concluded that existing national data on the incidence and
severity of pneumococcal disease in children younger than 5
years were either sparsely documented or of poor quality.
Abstracting estimates from a systematic review of regional data
on the burden of pneumococcal disease in children younger than
5 years in LAC countries, Nicaragua populated the model withd outcomes of ProVac country-owned cost-effectiveness
Paraguay
PCV-10 and PCV-13
 2þ1 schedule
 Evaluation period 2011–2020
 Societal perspective
s  3% discounting for costs and health benefits
 National Census (2002) and national demographic
projections
 Local and international disease burden studies
 Clinical trials and Cochrane review
 Historical DPT3 coverage
 Local costing exercise for nonvaccine costs
l  National household survey (2006)
0)  Local costing study in three subsectors (2009)
4 mo
 EPI manager
 Health economist
 Pediatrician
 PAHO country immunization advisor
Lab and surveillance officers
Final results presented to NITAG
 NITAG endorsed recommendation to introduce PCV-10
PP
 Government final report to support consultations with
parliament and Ministry of Finance to request budget
increase
Scenario analysis
One-way sensitivity analysis
s-pertussis vaccine; EPI, Expanded Program for Immunization; PPP,
visory Group; PAHO, Pan American Health Organization; PCV-10, 10-
al conjugate vaccine.
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radiologically confirmed pneumonia per 100,000, 11 episodes of
pneumococcal meningitis per 100,000, and 32 episodes of other
severe invasive pneumococcal disease per 100,000 [9]. Selected
parameters such as vaccine efficacy data were drawn from
published clinical trials. The national team decided that the local
data available for the remaining model parameters, including
vaccine coverage, program costs, and health service utilization
and disease management costs, were of good quality. With the
exception of disease burden data, Nicaragua’s cost-effectiveness
study of pneumococcal conjugate vaccine introduction primarily
considered local data.
At the request of the Ministry of Health, the national team
presented findings from the cost-effectiveness analysis in early
2011. Base-case analysis results indicated that both the PCV-10
and the PCV-13 vaccines would be cost-effective if introduced
universally with a 3þ0 schedule at a price per dose of $14.85
(Revolving Fund price) and of $0.36 (private-public partnership
(PPP) co-financing price), respectively. Cost-effectiveness thresh-
olds used were those defined by the WHO, in which an interven-
tion is considered cost-effective if the cost per disability-adjusted
life-year is less than three times the gross domestic product per
capita and highly cost-effective if less than one time the gross
domestic product per capita [10]. The data collected for the cost-
effectiveness study, in particular regional estimates on disease
burden and local data on circulating pneumococcal serotypes
and treatment costs, had alerted the national authorities to the
urgency with which the country should introduce a vaccine to
avert the substantial epidemiological and economic burden of
pneumococcal disease in the country. By late 2010, Nicaragua
decided to introduce PCV-13 because it was the only pneumo-
coccal conjugate vaccine approved for co-financing support from
PPP at an initial price to the country of $0.36 per dose and
guaranteed for a 5-year period.
In addition to the base-case results, Nicaragua presented a
series of alternative scenarios to communicate uncertainty
around future PPP co-financing and possible vaccine prices in
the absence of PPP support. The evaluation of the alternative
pricing scenarios, determined by actual prices offered through
PAHO’s Revolving Fund, decreasing PPP co-financing support, and
an assumed market price of US $20 per dose for both vaccines,
indicated that the introduction of either vaccine would be cost-
effective for the price ranges considered. However, the conclu-
sions that the vaccine was cost-effective did not imply that the
country would be able to afford the long-term investments
required to achieve a high-coverage vaccination program. None-
theless, the process of conducting a cost-effectiveness analysis
allowed for the country to begin answering questions to inform a
sustainable introduction. The Ministry of Health expressed that
the process of reviewing data on the impact of future financing
strategies was useful to evidence the need for resource mobiliza-
tion to ensure access to pneumococcal conjugate vaccination in
future years.
Experience from Paraguay
In late 2010, Paraguay requested technical support from PAHO to
conduct a cost-effectiveness analysis of the pneumococcal con-
jugate vaccines. Considered a high-level priority from the outset,
the Vice Minister of Health endorsed a ministerial decree (Min-
istry of Health Resolution S.G. No. 552) to establish a working
group responsible for collecting evidence to assess the need and
impact of vaccination against pneumococcal disease in the
younger than 5 years population. The ministerial decree officially
chartered and empowered a national team to undertake a ProVac
supported cost-effectiveness analysis and a financial feasibility
study on the potential adoption of a pneumococcal conjugatevaccine. The national team included the EPI manager, the PAHO
immunization country focal point, a health economist from the
Ministry of Finance, and a pediatrician. Additional support was
provided by the Ministry of Health laboratory and surveillance staff.
Paraguay chose to evaluate the costs and health benefits of
universal vaccination with a two-dose primary series and booster
dose (2þ1) schedule in 10 successive cohorts of children younger
than 5 years of age beginning in 2011. Like the experience of
Nicaragua, Paraguay underwent an extensive data collection
process, consulting several local sources. By December 2010, the
national team had collected sufficient information to populate all
model parameters. As was the case in Nicaragua, estimates for
disease burden were obtained from regional sources.
After concluding the study and performing scenario analysis,
the national team presented the findings to Paraguay’s NITAG.
The NITAG serves to review the available evidence base to make
recommendations to the Ministry of Health and inform national
immunization policy. During the January 2011 NITAG meeting,
the EPI manager presented the study findings, highlighting that
both PCV-10 and PCV-13 would be considered cost-effective
interventions in the Paraguayan context. However, PCV-10 was
slightly more cost-effective than PCV-13 due to the vaccine’s
greater protective effect against acute otitis media. By preventing
a greater number of acute otitis media cases, PCV-10 would avert
frequent health service costs associated with treating the infec-
tion in children borne by families. The EPI manager underscored
other important considerations. The study outcomes forecasted a
doubling of the EPI budget in the second year of introduction, as
assumed coverage efforts would undergo a rapid scale up. The
study findings also served to communicate data gaps identified in
the existing health information system, such as poor and dis-
parate local disease burden data. NITAG members made a call to
improve surveillance systems in order to have better quality data
to inform decisions.
The primary outcome of the NITAG meeting was a formal
recommendation to the Ministry of Health to introduce PCV-10.
In part, the country’s decision to introduce PCV-10 was influenced
by the availability of only one pneumococcal conjugate vaccine in
PAHO’s Revolving Fund, a pooled procurement mechanism. The
NITAG recommended using the Revolving Fund’s transparent
procurement mechanism to guarantee an uninterrupted supply
of WHO prequalified vaccines at the best available price. With the
results in hand, the EPI manager began informal consultations
with members of parliament to seek the necessary budgetary
increases to support universal introduction of PCV-10 in the near
term. In addition, the Minister of Health used the study findings
to lobby for a substantial expansion to the immunization pro-
gram budget with the Ministry of Finance.Discussion
The experience of Nicaragua and Paraguay signals the capacity of
public health professionals to incorporate cost-effectiveness
analysis into the decision-making process for new vaccine
introduction when country teams have access to adequate tools
and training for their use. Through reviewing how country teams
applied decision-support tools and methods in the new vaccine
introduction decision-making process, five key lessons were
identified.
CEA Results Are Not Generalizable
Because several countries in the Americas have conducted CEA
on the pneumococcal conjugate vaccines, the remaining coun-
tries that have not conducted studies may consider applying
study results and neighboring country recommendations in their
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demonstrates that cost-effectiveness results are influenced by
several country-specific factors and processes (Table 2). The two
case studies highlight that despite grounding decisions in evidence,
even similar cost-effectiveness results can lead to different new
vaccine introduction decisions. Both vaccines represented ‘‘value
for money’’ in Nicaragua and Paraguay, but the countries chose to
introduce different vaccines. There are several reasons for this.
First, the process of conducting cost-effectiveness analysis can shed
light on other important considerations such as budgetary implica-
tions, which can be different from one country to another. Second,
countries have unique characteristics such as PPP eligibility, which
is an important factor for estimating long-term incremental costs to
the vaccination program. And third, countries can prioritize differ-
ent criteria for introduction, such as whether a certain vaccine can
be procured through a more reliable and efficient mechanism.
Therefore, the results of country-level CEA cannot be extrapolated
to neighboring countries, and much less to make a recommenda-
tion for which vaccine to introduce.
A Framework for Building Up Timely Evidence Bases Is Critical
Model-based economic analyses are data-intensive, requiring the
synthesis of information from disparate sources. These analyses
provide a framework to begin collecting and analyzing the multiple
layers of evidence relevant in the decision-making process. The
iterative data collection and analysis process of disparate sources
required for model-based economic analyses helps countries build
up the evidence base around new vaccine introduction even before
final results are obtained. For example, Nicaragua’s final cost-
effectiveness results came after the decision had already been
made on the basis of an offer of a greatly subsidized price per dose
for PCV-13, but the need to introduce the vaccine was evidenced in
the early stages of data collection and analysis. Authorities knew
that price subsidies for the pneumococcal conjugate vaccines were
time bound and would not last forever, and the study exposed the
substantial burden of pneumococcal disease in the country. The
process of collecting and analyzing data necessary for the cost-
effectiveness analysis signaled authorities early-on of the need to
introduce the vaccine.
CEA Alone Cannot Answer All New Vaccine Policy Questions
Considering the current economic climate and constrained health
budgets in the PAHO region, countries need answers to several
questions to ensure efficient and equitable resource allocation for
health. An important component of the evidence base for immu-
nization policy, CEA can determine the relative value of introducing
a new vaccine versus status quo; however, subsequent analyses are
required to answer more complex policy questions around afford-
ability and financial sustainability amid competing health priorities.
In the example of Paraguay, a financial feasibility study was
conducted to understand how the introduction of a pneumococcal
vaccine would affect the program’s current budget and spending
trends. In addition to supplemental analyses, countries should seek
to contextualize cost-effectiveness results with other technical,
operational, and social criteria. Standardized decision cases, or
short, concise policy documents targeting high-level public health
decision makers, could include the evaluation of other evidence
criteria to complement cost-effectiveness findings.
Country-Led Economic Evaluations Are a Useful Tool for Price
Negotiation
Cost-effectiveness results can be an effective tool for negotiating
prices, allowing governments to save more lives with their limited
resources. The threshold from cost-effective to highly cost-effective
or another national-level threshold can be used as negotiating powerto access a lower price for the vaccine. In Nicaragua, estimating the
cost-effectiveness of PCV-13 at different prices per dose as well as
the resulting budgetary impacts gave the country a potentially
powerful tool to mediate discussions with PPP about future co-
financing support. At the same time, the secondary analysis allowed
for decision makers to reflect on the resource needs to sustain
vaccination against pneumococcal disease in the long term if PPP co-
financing support were no longer available after the initial 5-year
agreement. Even though favorable cost-effectiveness results for a
new vaccine do not signal affordability for immunization programs,
cost-effectiveness evidence canmake it easier for decisionmakers to
justify the national investment.
Effectively Channeling Cost-Effectiveness Results and
Educating Decision Makers Is Key
While CEA has the potential to guide resource allocation and
improve rational decision making, findings need to be channeled
through key policy actors to have a tangible impact on the
immunization policy. ProVac attempts to build infrastructure to
improve communication between actors to increase the potential
for informed, evidence based decision making. Paraguay’s experi-
ence suggests that evidence reaches the decision maker more
effectively when the relevant actors in the immunization policy
arena are involved from the beginning. Early buy-in from the Vice-
Minister of Health in Paraguay empowered the EPI manager and the
national team to defend study results in front of a wide audience of
policymakers, including parliamentarians. Another crucial factor
for ensuring CEA considered in the decision-making process is the
need to educate NITAG members and high-level authorities in the
Ministry of Health on what types of information may be useful for
prioritizing public health investments. Cost-effectiveness results
can only be useful insomuch as the policymakers are aware of the
advantages and limitations of economic analyses. For example,
Nicaragua’s experience illustrated how a relatively complex con-
cept, such as uncertainty analysis, can be an effective tool for
decision makers when simultaneous education and proper com-
munication about its use is provided. Using the lower and upper
limits of a few key parameters, such as vaccine efficacy, disease
burden, and vaccine price per dose, showed national authorities
that the vaccine was still considered cost-effective in a scenario
unfavorable to the vaccine.Conclusions
Policy questions and needs for technical support in the national
decision-making process for new vaccine introduction continue to
evolve in LAC. Implementation of PAHO’s ProVac Initiative in LAC
countries demonstrates how country-led economic analyses can
help build capacity and infrastructure to make more informed,
evidence-based decisions. Multidisciplinary country teams that
gather the evidence base for public health policy are an essential
component of this process. Government-sustained multidisciplin-
ary country teams that generate, synthesize, and present evidence
to decision makers are an effective instrument for promoting
evidence-based immunization policy. The vision going forward for
the ProVac Initiative will focus on promoting the sustainability of
multidisciplinary country teams while continuing to prioritize
capacity development as an overarching guiding principle for
preparing countries to face future new vaccine policy decisions. In
addition, the lessons learned from the initial experiences in LAC
countries with country-led economic analyses to inform immuni-
zation policy will help inform the application of the ProVac
approach for country support in other regions of the world. As
PAHO’s ProVac Initiative continues to support evidence-based
decision making for new vaccine introduction in the Americas, it
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